Silkoff Philip E, Singh Dave, FitzGerald J Mark, Eich Andreas, Ludwig-Sengpiel Andrea, Chupp Geoffrey C, Backer Vibeke, Porsbjerg Celeste, Girodet Pierre-Olivier, Dransfield Mark T, Baribaud Frederic, Susulic Vedrana S, Loza Matthew J
Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, UK.
Biomark Insights. 2017 Sep 7;12:1177271917730306. doi: 10.1177/1177271917730306. eCollection 2017.
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and development of novel therapeutics requires an understanding of pathophysiologic phenotypes.
The purpose of the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study was to correlate clinical features and biomarkers with molecular characteristics in a well-profiled COPD cohort.
A total of 67 COPD subjects (forced expiratory volume in the first second of expiration [FEV]: 45%-80% predicted) and 63 healthy smoking and nonsmoking controls underwent multiple assessments including patient questionnaires, lung function, and clinical biomarkers including fractional exhaled nitric oxide (FENO), induced sputum, and blood.
The impact of inhaled corticosteroids (ICSs), and to a lesser extent current smoking, was more associated with symptom control, exacerbation rates, and clinical biomarkers, than severity by FEV. The ICS-treated smoking subjects were most symptomatic, with significantly elevated scores on patient-reported outcomes and more annual exacerbations ( < .05). Inhaled corticosteroid users had greater airflow obstruction and air trapping compared with non-ICS users, regardless of smoking status. Smoking, regardless of ICS use, was associated with significantly lower FENO ( < .05). Smoking, in non-ICS users, was associated with an elevated proportion of sputum neutrophils and reduced sputum macrophages. Increased serum C-reactive protein was observed in smokers but not in ICS and nonsmoking ICS users ( < .05). In contrast, only air trapping and neutrophilic inflammation increased with severity, defined by postbronchodilator FEV.
Compared with COPD severity by FEV, ICS use and current smoking were better determinants of clinical characteristics and biomarkers. Use of the ADEPT COPD data promises to prove useful in defining biological phenotypes to facilitate personalized therapeutic approaches.
慢性阻塞性肺疾病(COPD)是一种异质性疾病,开发新的治疗方法需要了解其病理生理表型。
个性化治疗气道疾病分型(ADEPT)研究的目的是在一个特征明确的COPD队列中,将临床特征和生物标志物与分子特征相关联。
总共67名COPD受试者(第一秒用力呼气容积[FEV]:预测值的45%-80%)以及63名健康吸烟和非吸烟对照者接受了多项评估,包括患者问卷、肺功能以及临床生物标志物,如呼出一氧化氮分数(FENO)、诱导痰和血液检测。
吸入性糖皮质激素(ICS)的影响,以及在较小程度上当前吸烟情况,与症状控制、急性加重率和临床生物标志物的关联,比FEV所反映的严重程度更为密切。接受ICS治疗的吸烟受试者症状最为明显,患者报告结局得分显著升高,且年度急性加重次数更多(P<0.05)。与非ICS使用者相比,无论吸烟状态如何,吸入性糖皮质激素使用者的气流阻塞和气体潴留更为严重。无论是否使用ICS,吸烟均与显著更低的FENO相关(P<0.05)。在非ICS使用者中,吸烟与痰中性粒细胞比例升高和痰巨噬细胞减少相关。吸烟者血清C反应蛋白升高,但ICS使用者和非吸烟的ICS使用者中未观察到这种情况(P<0.05)。相比之下,只有气体潴留和中性粒细胞炎症随支气管扩张剂后FEV所定义的严重程度增加。
与FEV所反映的COPD严重程度相比,ICS使用情况和当前吸烟状况是临床特征和生物标志物更好的决定因素。利用ADEPT研究中的COPD数据,有望在定义生物学表型以促进个性化治疗方法方面发挥作用。